Medicare Advantage Wound Care Denials: The PA Nightmare

If you are billing wound care services to Medicare Advantage plans, you already know the pain. The denial rate on MA claims consistently runs higher than fee-for-service Medicare — often two to three times higher for skin substitute applications, NPWT, and advanced wound therapies. The prior authorization requirements are more burdensome, the turnaround times are longer, and the clinical criteria are frequently more restrictive than CMS national coverage policy.

This is not a billing error problem. This is a structural problem with how Medicare Advantage plans manage wound care coverage, and it requires a structural solution.

Why MA Plans Deny More Than FFS Medicare

Understanding the incentive structure explains the behavior. Fee-for-service Medicare pays claims that meet published coverage criteria. The MAC reviews documentation, applies LCD requirements, and pays or denies based on whether the submitted records match the coverage policy. The incentive is neutral — CMS does not profit from denials.

Medicare Advantage plans operate on a fundamentally different model. They receive a capitated per-member-per-month (PMPM) payment from CMS for each enrolled beneficiary. Every claim they pay comes out of that capitation. Every claim they deny stays in it. The financial incentive is to manage utilization — which, in practice, means denying or delaying claims that fee-for-service Medicare would have paid.

This incentive structure produces several predictable behaviors that wound care practices encounter daily.

Stricter Prior Authorization Requirements

FFS Medicare does not require prior authorization for most wound care services. You provide the service, document it according to LCD requirements, and submit the claim. The MAC reviews the documentation and pays or denies.

MA plans layer prior authorization on top of the LCD requirements. Before you can apply a skin substitute, you may need to submit a PA request that includes wound measurements, photographic documentation, treatment history demonstrating failure of conservative therapy, and a clinical justification for why this specific product is medically necessary for this specific patient.

The PA process can take 5 to 15 business days — during which the patient's wound is not receiving the treatment your clinical judgment says it needs. And a PA approval does not guarantee payment. The claim can still be denied post-service if the documentation does not meet the plan's clinical criteria, even if the PA was approved.

Plan-Specific Clinical Criteria

FFS Medicare coverage for wound care services is governed by LCDs published by the seven MACs. While there is MAC-level variation, the criteria are publicly available and relatively consistent.

MA plans are not required to follow LCD criteria. They can — and do — impose their own clinical criteria for coverage. Some MA plans require wound measurement documentation at specific intervals. Others require proof of vascular assessment before covering skin substitute application on lower extremity wounds. Some require that conservative therapy be attempted for a specific number of weeks before advanced therapies are covered — and their definition of "conservative therapy" may not match the LCD definition.

The challenge is that these criteria are often buried in provider manuals, vary by plan, and change without notice. A service that was covered under Plan A's criteria last quarter may not be covered under the same plan's updated criteria this quarter.

Retrospective Denials After PA Approval

Perhaps the most frustrating pattern: the plan approves the PA, you provide the service, you submit the claim — and it gets denied. The reason is typically a documentation technicality: the wound measurement on the claim date did not match the measurement on the PA submission, or the treatment plan documented in the clinical note differed from the plan described in the PA request, or the product applied was a different lot number from what was authorized.

These retrospective denials are financially and operationally expensive. You have already incurred the product cost, the clinician's time, and the billing cost. The denial means you absorb all of those costs and start the appeals process.

The PA Workflow That Prevents Denials

The practices that maintain manageable denial rates on MA claims do so by building PA compliance into their clinical workflow — not by training harder or hiring more billing staff, but by designing operational systems that make PA errors structurally unlikely.

Step 1: Identify PA Requirements Before the First Visit

When a new patient is referred with Medicare Advantage coverage, identify their specific plan and check the PA requirements before scheduling the first visit. Do not assume MA plans have uniform requirements. Aetna Medicare Advantage, Humana Gold Plus, and UnitedHealthcare AARP are three different plans with three different PA policies.

Build a PA requirements matrix for every MA plan you accept. At minimum, track:

Which services require PA (skin substitutes, NPWT, HBO, advanced wound therapies)
What documentation the PA submission requires (measurements, photos, treatment history, clinical justification)
PA submission method (online portal, fax, phone)
Typical turnaround time
PA validity period (how long the approval lasts — 30 days? 90 days? Per application?)

This matrix should be accessible to your clinical team in the field. When a clinician assesses a wound and determines that a skin substitute application is indicated, they need to know immediately whether a PA is required for that patient's plan and what documentation they need to capture during this visit to support the PA submission.

Step 2: Submit PA With Overcomplete Documentation

PA reviewers deny unclear submissions. They approve comprehensive ones. The strategy is to submit more documentation than the plan technically requires, not less.

For a skin substitute PA, a complete submission should include:

Wound measurements (length, width, depth) from the most recent visit
Wound photographs with a ruler for scale
Treatment timeline showing all conservative therapies attempted, with dates and outcomes
Clinical rationale explaining why conservative therapy has failed and advanced therapy is medically necessary
Product specification — the exact product, manufacturer, and HCPCS Q-code you intend to use
Frequency request — how many applications you anticipate, at what interval

Do not write the clinical rationale in a sentence. Write it in a paragraph. Explain the wound etiology, the patient's comorbidities that impair healing, the specific conservative therapies attempted and their documented failure, and why the proposed product is appropriate for this wound type. Make it easy for the PA reviewer to approve.

Step 3: Track PA Status and Expiration

PA approvals expire. A PA approved on January 15 with a 90-day validity period expires on April 15. If you apply a skin substitute on April 20, the claim will be denied — even though the PA was approved for that service.

Track every active PA with an expiration date. If a patient's treatment plan extends beyond the PA validity period, submit a renewal PA before the expiration date, not after. The renewal submission should include updated wound measurements and a progress note demonstrating that continued treatment is medically necessary.

Step 4: Mirror PA Documentation in the Clinical Note

When you provide the PA-authorized service, ensure that the clinical documentation mirrors what was submitted in the PA request. If the PA specified application of product X to a 4.5 cm x 3.2 cm wound, the clinical note for the application visit should document the same product and current wound measurements that are consistent with the clinical trajectory described in the PA.

Inconsistencies between the PA submission and the clinical note are the most common trigger for retrospective denials. The PA said the wound was 4.5 x 3.2 cm. The clinical note says 5.1 x 3.8 cm. The reviewer flags this as a discrepancy. Document why the measurement changed (wound deterioration, measurement variance) rather than leaving the discrepancy unexplained.

Appeals: The Cost of Doing Business

Even with rigorous PA compliance, MA plan denials will happen. The question is not whether you will need to appeal — it is whether your appeals process is efficient enough to make the recovery worthwhile.

First-level appeal success rates on MA wound care denials run between 40 and 60 percent for practices with good documentation. If you are below 40 percent, your clinical documentation has systemic gaps. If you are above 60 percent, the plan is denying claims it should be paying — which is unfortunately common.

Key appeal strategies:

Appeal within the plan's timeline. Most MA plans have a 60-day appeal window. Missing the deadline converts a reversible denial into a permanent write-off.
Include additional documentation. If the denial reason was "insufficient documentation of medical necessity," the appeal is your opportunity to provide the clinical narrative that the initial submission lacked. Do not simply resubmit the same documentation with a cover letter that says "please reconsider."
Reference CMS coverage criteria. MA plans are contractually required to cover services that FFS Medicare covers. If the denial is based on plan-specific criteria that are more restrictive than the applicable LCD, cite the LCD and the CMS requirement that MA plans provide coverage at least equivalent to FFS Medicare.
Track denial patterns by plan. If one MA plan is denying 30 percent of your skin substitute claims while another denies 8 percent, the problem is plan-specific. Consider whether the high-denial plan is worth accepting, or whether your documentation for that plan's specific criteria needs adjustment.

The Payer Mix Decision

Some wound care practices solve the MA denial problem by limiting the number of MA plans they accept. This is a legitimate business decision, but it comes with trade-offs.

MA enrollment has been growing steadily and now covers more than half of all Medicare beneficiaries. Refusing to accept MA plans means turning away a growing portion of the wound care patient population. In some markets, the majority of Medicare-eligible wound care patients are enrolled in MA plans.

The alternative to limiting MA plan acceptance is building the operational infrastructure to manage MA billing efficiently. That means PA tracking systems, documentation templates that capture MA-specific requirements, and appeals workflows that recover revenue from denied claims.

Neither approach is wrong. But the decision should be informed by data — your denial rate by plan, your appeal success rate, your cost per PA submission, and the volume of referrals you would lose by dropping specific plans.

For the full picture on MA billing strategy, see Wound Care Medicare Advantage Billing and Wound Care Prior Authorization.

The Structural Problem Requires a Structural Solution

MA wound care denials are not going away. The incentive structure that produces them is inherent to the MA model, and CMS regulatory efforts to curb inappropriate denials have been incremental. Practices that treat MA denials as a billing department problem — something to be solved by training coders or hiring another biller — will stay on the treadmill.

The practices that manage MA billing successfully build the compliance infrastructure into the clinical workflow. PA requirements are visible to the clinician before the visit. Documentation templates capture the specific elements each plan requires. PA expiration dates are tracked automatically. Clinical notes mirror PA submissions by design, not by chance.

This is not about working harder. It is about designing systems where the right thing happens by default.

Managing prior authorizations, tracking PA expiration dates, and aligning clinical documentation with plan-specific requirements is operational infrastructure that belongs in your clinical workflow, not in a separate spreadsheet. If you are evaluating platforms that integrate PA management with wound care documentation, see how Medipyxis approaches payer compliance.